Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32

Morgan Stanley analyst Michael Ulz has initiated coverage on Adarx Pharmaceuticals (NASDAQ: ADRX) with an Overweight rating. The firm has set a price target of $32 for the company's stock.